Drugs / ZORACOPAN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06173596 | Jan → Apr 2024 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06160414 | Apr 2023 → Feb 2024 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05428696 | Sep 2022 → Apr 2023 | — | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZORACOPAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6017042 ↗ |
| Known as | ALXN2080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06173596 ↗ |
| Modality | Small molecule | — CHEMBL6017042 ↗ |
| Route | Oral | “receive ALXN2080 orally” NCT06160414 ↗ |